1. A compound of the formula (I)
and analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof, wherein – – – represents an optional bond; V represents CH or N; Y represents O or S; W represents O or NR8; R8 is selected from hydrogen or linear, branched, substituted or unsubstituted (C1-C6) alkyl groups; X represents CR9, O or S wherein R9 is hydrogen or R9 together with Z forms a 5 or 6-membered aromatic or heteroaromatic ring system containing 1 to 2 heteroatoms selected from O, S or N;; Z represents O, S or together with R9 forms a 5 to 6 membered aromatic or heteroaromatic ring system containing 1 to 2 hetero atoms selected from O, S or N; R1 and R2 may be same or different and are independently selected from hydrogen, a halogen, hydroxy, nitro, cyano, formyl, amino, COR10 or linear, branched, substituted or unsubstituted (C1-C6) alkyl group; or substituted or unsubstituted (C1-C6) alkoxy group; R10 represents \u2014OR11 or NR12R13; where R11 represents hydrogen, a substituted or unsubstituted group selected from alkyl, alkenyl, aryl, aralkyl, heteroaryl, or a counter ion; R12 and R13 may be same or different and independently represent H or substituted or unsubstituted alkyl, alkenyl or aryl groups; ; or R12 and R13 together form a heteroaliphatic or heteroaromatic ring; R3, R4, R5 and R6, are selected from hydrogen, halogen; hydroxy, nitro, cyano, formyl, amino, linear or branched, substituted or unsubstituted (C1-C6) alkyl or alkoxy groups; haloalkyl groups, carboxylic acid and its derivatives; unsubstituted sulfonamide, sulfonyl methyl group; R7 represents hydrogen, substituted or unsubstituted alkyl, alkenyl, \u2014CH2COOR, aryl groups, or a counter ion; where R represents H or (C1-C6) alkyl group.
2. A compound according to claim 1, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof, wherein Y is O; X is S or CR9; R1 is COR10 and R2 is hydrogen or alkyl.
3. A compound according to claim 2, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof, wherein R3 is hydrogen or halo; R4 and R6 are hydrogen; R5 is hydrogen, halo, haloalkyl or alkoxy; and R7 is hydrogen, \u2014CH2COOR or a counterion.
4. A compound according to claim 3, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof, wherein V is CH; X is S; Y, Z and W are O; R10 is \u2014OR11; R11 is hydrogen or a counterion; R2, R3, R4, R5 and R6 are hydrogen; and R7 is hydrogen or a counterion.
5. A compound according to claim 3, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof, selected from:
{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-acetic acid;
{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-acetic acid disodium salt;
{4-4-(4-Oxo-2-thioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-acetic acid;
{4-4-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-acetic acid;
{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-fluoro-phenoxy-phenyl}-acetic acid;
{4-2-Chloro-4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-acetic acid;
{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-trifluoromethyl-phenoxy-phenyl}-acetic acid;
{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-methoxy-phenoxy-phenyl}-acetic acid;
{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-3-fluoro-phenoxy-phenyl}-acetic acid;
{4-4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-phenoxy-phenyl}-acetic acid;
{4-4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2-trifluoromethyl-phenoxy-phenyl}-acetic acid;
{4-4-(4-Oxo-2-thioxo-thiazolidin-5-ylmethyl)-2-trifluoromethyl-phenoxy-phenyl}-acetic acid;
{4-4-(4-Oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-phenoxy-phenyl}-acetic acid;
{4-4-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-phenoxy-phenyl}-acetic acid;
{4-4-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylmethyl)-3-fluoro-phenoxy-phenyl}-acetic acid;
{6-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenoxy-pyridin-3-yl}-acetic acid;
{6-4-(4-Oxo-2-thioxo-thiazolidin-5-ylmethyl)-phenoxy-pyridin-3-yl}-acetic acid;
{6-4-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylmethyl)-phenoxy-pyridin-3-yl}-acetic acid;
{6-4-(2-Oxo-2,3-dihydro-1H-indol-3-ylmethyl)-phenoxy-pyridin-3-yl}-acetic acid;
{6-4-(2-Oxo-2,3-dihydro-1H-indol-3-ylmethyl)-2-trifluoromethyl-phenoxy-pyridin-3-yl}-acetic acid;
{4-4-(2-Oxo-2,3-dihydro-1H-indol-3-ylmethyl)-2-trifluoromethyl-phenoxy-phenyl}-acetic acid;
{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenoxy-2-fluoro-phenyl}-acetic acid;
2-{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-N,N-dimethyl-acetamide;
2-{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-acetamide;
5-{4-4-(2-Oxo-2-piperazin-1-yl-ethyl)-phenoxy-benzyl}-thiazolidine-2,4-dione;
5-{4-4-(2-Morpholin-4-yl-2-oxo-ethyl)-phenoxy-benzyl}-thiazolidine-2,4-dione;
2-{4-4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-butyric acid;
(4-{4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenyl-methyl-amino}-phenyl)-acetic acid; or
5-{4-4-(2-Oxo-2-piperazin-1-yl-ethyl)-phenoxy-3-trifluoromethyl-benzyl}-thiazolidine-2,4-dione.
6. The compound {4-4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-acetic acid.
7. The compound {4-4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy-phenyl}-acetic acid disodium salt.
8. A compound according to claim 1 wherein the said pharmaceutically acceptable salt is selected from the group consisting of a hydrochloride, hydrobromide, sulfate, besylate, sodium, potassium, calcium and magnesium salt.
9. A pharmaceutical composition comprising a therapeutically effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according to any one of claims 1 to 8 sufficient to reduce in a subject the plasma level of glucose, fatty acids, cholesterol or triglycerides and a pharmaceutically acceptable carrier, diluent, excipient or solvate.
10. A pharmaceutical composition comprising a therapeutically effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according to any one of claims 1 to 8 sufficient to treat obesity, autoimmune diseases, inflammation, immunological diseases, diabetes or disorders associated with insulin resistance in a subject.
11. A pharmaceutical composition according to claim 9 in the form of a tablet, capsule, powder, syrup, aerosol or suspension.
12. A pharmaceutical composition according to claim 10 in the form of a tablet, capsule, powder, syrup, aerosol or suspension.
13. A method for reducing the glucose level in the plasma comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
14. A method for reducing the free fatty acid level in the plasma comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
15. A method for reducing the cholesterol level in the plasma comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
16. A method for reducing the triglyceride level in the plasma comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
17. A method for treating diabetes comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
18. A method for treating obesity comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
19. A method for treating autoimmune diseases comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
20. A method for treating cancer comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
21. A method for treating inflammation comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
22. A method for treating immunological disease comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
23. A method for treating the disorders associated with insulin resistance comprising administering an effective amount of a compound or a mixture of compounds, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according claim 1 to a patient in need thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A sheet tray device that is removably introduced into a main body of an image forming apparatus through an opening of the main body, so as to hold a media sheet that is to be supplied to an image forming unit of the image forming apparatus by which an image forming operation is performed on the media sheet, said sheet tray device comprising:
(a) a first tray accommodating a first size sheet as the media sheet, and having a bottom wall and opposite side walls that project upwardly from said bottom wall, such that at least said bottom wall and said opposite side walls are provided by a single piece; and
(b) a second tray movably disposed on an upper side of said first tray and accommodating a second size sheet as the media sheet, the second size sheet having a size smaller than a size of the first size sheet,
wherein said second tray includes (b-1) a support member which bridges between said opposite side walls of said first tray and which is movable relative to said opposite side walls, and (b-2) a supported body pivotably supported by said support member so as to open and close an upper opening of said first tray,
wherein each of said opposite side walls of said first tray includes first and second rail portions that extend in a rail extending direction in which said support member is movable relative to said opposite side walls, said second rail portion being located on an upper side of said first rail portion and being spaced apart from said first rail portion,
wherein said support member of said second tray includes (i) a main slide portion that is slidably held in contact with an upper surface of said first rail portion, (ii) a removal-preventing slide portion that extends through a space between said first and second rail portions so as to prevent removal of said support member of said second tray from said first tray, and (iii) a rotation-preventing slide portion that is slidably held in contact with a side surface of said first rail portion so as to prevent rotation of said support member of said second tray relative to said first tray,
wherein said first and second rail portions are offset from each other in a lateral direction in which said opposite side walls of said first tray are opposed to each other, such that said first and second rail portions do not overlap with each other as seen in a vertical direction that is perpendicular to said lateral direction and said rail extending direction,
wherein said support member of said second tray further includes (iv) an extending wall portion which extends from said removal-preventing slide portion, such that said first rail portion is located between said extending wall portion and said rotation-preventing slide portion in said lateral direction,
wherein said rotation-preventing slide portion extends downwardly from said main slide portion, and is slidably held in contact with, as said side surface, one of opposite side surfaces of said first rail portion that is located on an inner side of the other of said opposite side surfaces in said lateral direction,
wherein said removal-preventing slide portion extends outwardly from said main slide portion in said lateral direction,
and wherein said extending wall portion extends downwardly from said removal-preventing slide portion, such that said extending wall portion, said removal-preventing slide portion, said main slide portion and said rotation-preventing slide portion cooperate with one another to define a generally inverted U shape in a cross-section thereof that is perpendicular to said rail extending direction.
2. The sheet tray device according to claim 1,
wherein said extending wall portion has an opposed surface that is opposed to said first rail portion in said lateral direction,
and wherein said opposed surface is inclined such that a distance between said opposed surface and said first rail portion increases in a downward direction away from said upper surface of said first rail portion.
3. The sheet tray device according to claim 1, wherein said rotation-preventing slide portion of said support member has a length as measured in said rail extending direction, while said support member has a length as measured in said rail extending direction, such that said length of said rotation-preventing slide portion and said length of said support member are substantially equal to each other.
4. The sheet tray device according to claim 1, wherein said rotation-preventing slide portion of said support member extends in said rail extending direction substantially throughout an entirety of said support member.
5. An image forming apparatus comprising:
the sheet tray device defined in claim 1;
an image forming unit performing an image forming operation on a media sheet; and
a sheet supplying unit supplying the media sheet held by said sheet tray device, to said image forming unit.
6. The sheet tray device according to claim 1, wherein said first and second rail portions are offset from each other in said lateral direction such that said second rail portion located on an outer side of said first rail portion in said lateral direction.
7. The sheet tray device according to claim 6, wherein said single piece providing at least said bottom wall and said opposite side walls of said first tray is a product that is molded in an injection molding using upper and lower mold halves.
8. The sheet tray device according to claim 7, wherein said single piece is made of a resin.
9. The sheet tray device according to claim 1, wherein each of said first and second rail portions is provided by a plate-like shaped portion having a width as measured in said vertical direction and a thickness as measured in said lateral direction such that said width is larger than said thickness.